Last $8.81 USD
Change Today -0.01 / -0.11%
Volume 1.5M
OPK On Other Exchanges
Symbol
Exchange
New York
Berlin
Mexico
Tel Aviv
As of 8:04 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

opko health inc (OPK) Snapshot

Open
$8.84
Previous Close
$8.82
Day High
$8.85
Day Low
$8.75
52 Week High
10/16/13 - $12.95
52 Week Low
02/5/14 - $7.32
Market Cap
3.6B
Average Volume 10 Days
2.7M
EPS TTM
$-0.29
Shares Outstanding
412.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OPKO HEALTH INC (OPK)

opko health inc (OPK) Related Businessweek News

View More BusinessWeek News

opko health inc (OPK) Details

Opko Health, Inc., a biopharmaceutical and diagnostics company, is engaged in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company develops a range of solutions to diagnose, treat, and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals, and vaccines. Its product pipeline includes various pharmaceutical compounds and technologies in research and development for a range of indications and conditions. The company’s lead products comprise RayaldyTM, a vitamin D prohormone, which in phase III clinical development stage to treat secondary hyperparathyroidism in patients with stage III or IV chronic kidney disease and vitamin D insufficiency; and Alpharen, a new and potent non-absorbed phosphate binder to treat hyperphosphatemia in dialysis patients. It also manufactures, sells, and licenses specialty active pharmaceutical ingredients for pharmaceutical companies. In addition, the company is involved in the discovery of new drugs for the treatment of various illnesses, including cancer, heart disease, metabolic disorders, and genetic anomalies; and developing a protein-based influenza vaccine that would offer protection against influenza, as well as has various therapeutic agents for respiratory disorders in clinical development, including products for asthma, chronic obstructive pulmonary disease, and chronic cough. Further, it develops rolapitant, a potent and selective competitive antagonist that has completed phase II clinical testing for prevention of chemotherapy induced nausea and vomiting. It also operates OPKO Lab, a full-service medical laboratory specializing in urologic pathology. The company operates in the United States, Chile, Spain, Israel, Mexico, and Ireland. OPKO Health, Inc. is based in Miami, Florida.

625 Employees
Last Reported Date: 03/3/14

opko health inc (OPK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $492.3K
Vice Chairman and Chief Technical Officer
Total Annual Compensation: $482.3K
Executive Vice President of Administration an...
Total Annual Compensation: $455.0K
Consultant
Total Annual Compensation: $275.0K
Compensation as of Fiscal Year 2013.

opko health inc (OPK) Key Developments

Opko Health, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Opko Health, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, revenues were $23.5 million compared to $23.8 million a year ago. Operating loss was $34.9 million compared to $18.0 million a year ago. Loss before income taxes and investment losses was $25.6 million compared to $1.1 million a year ago. Net loss was $26.1 million compared to $4.4 million a year ago. Net loss attributable to common shareholders was $25.5 million or $0.06 basic and diluted per share compared to $3.4 million or $0.01 basic and diluted per share a year ago. For the six months, revenues were $45.8 million compared to $55.2 million a year ago. Operating loss was $65.2 million compared to $24.8 million a year ago. Loss before income taxes and investment losses was $68.0 million compared to $31.9 million a year ago. Net loss was $71.1 million compared to $39.1 million a year ago. Net loss attributable to common shareholders was $70.0 million or $0.17 basic and diluted per share compared to $38.0 million or $0.12 basic and diluted per share a year ago.

OPKO Health, Inc. Announces Top-Line Results from the First Pivotal Phase 3 Trial of Rayaldee(TM)

OPKO Health, Inc. announced top-line results from the first pivotal phase 3 trial of Rayaldee(TM). This trial is one of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Both trials are the subject of a Special Protocol Assessment (SPA) established with the United States (U.S.) Food and Drug Administration (FDA) in August 2012. This trial involved 213 adult patients recruited from 39 sites throughout the U.S. Patients were stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either Rayaldee or placebo. On enrollment, all patients exhibited vitamin D insufficiency which was corrected in 96% of patients treated with Rayaldee. The completed trial met all primary efficacy and safety endpoints. The primary efficacy endpoint was a responder analysis in which responder was defined as any treated subject who demonstrated an average 30% decrease in plasma parathyroid hormone (PTH) from pre-treatment baseline during the last six weeks of the treatment period. A significantly higher response rate (p<0.001) was observed with Rayaldee which steadily increased with treatment duration. The response rate with Rayaldee was similar in CKD stages 3 and 4. Safety and tolerability data were comparable in both treatment groups.

Opko Health, Inc. to Report Q2, 2014 Results on Aug 11, 2014

Opko Health, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 11, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OPK:US $8.81 USD -0.01

OPK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OPK.
View Industry Companies
 

Industry Analysis

OPK

Industry Average

Valuation OPK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.8x
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OPKO HEALTH INC, please visit www.opko.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.